As a leader in muscle biology, we have a robust pipeline of small molecule muscle activators and inhibitors to address diseases characterized by compromised muscle function, including heart failure, hypertrophic cardiomyopathy (HCM Disease), and neuromuscular diseases.
Cytokinetics is powered by passion with patients as our North Star. Our mission is to develop new medicines that may improve outcomes for those living with debilitating diseases of cardiovascular and neuromuscular muscle dysfunction.
Learn more about our mission vision, drug development, pipeline and clinical development in our corporate presentation.
For more than 25 years, Cytokinetics, a late-stage biopharmaceutical company, has been finding strength in science as a pioneer in the field of muscle biology working to discover, develop, and commercialize potential medicines that may preserve and extend independence in people suffering from debilitating diseases.
Company operations begin in South San Francisco.
Becomes a publicly traded company, fueling the opportunity to expand and accelerate the development programs.
Company focuses research activities to muscle biology.
Clinical trials begin for the first potential cardiac myosin inhibitor.
Cardiovascular disease is the leading cause of death in the U.S., with one person dying from related diseases every 34 seconds.1 We’re committed to building a specialty cardiology business to bring forward treatment options that make a difference for the millions of patients impacted by heart failure and hypertrophic cardiomyopathy.
Learn about Heart Failure Learn about Hypertrophic Cardiomyopathy
Cytokinetics is a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with debilitating diseases.
We are committed to keeping patients at the center of our work, advancing a high integrity, diverse and inclusive culture, and supporting a more sustainable world.
We provide more than a job. We provide an opportunity to contribute to something bigger than any one of us. We seek exceptional individuals who share our vision of improving the lives of patients with compromised muscle function.
References